Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme

被引:275
作者
Park, John K.
Hodges, Tiffany
Arko, Leopold
Shen, Michael
Dello Iacono, Donna
McNabb, Adrian
Bailey, Nancy Olsen
Kreisl, Teri Nguyen
Iwamoto, Fabio M.
Sul, Joohee
Auh, Sungyoung
Park, Grace E.
Fine, Howard A.
Black, Peter McL.
机构
[1] NINDS, Surg & Mol Neurooncol Unit, Neurooncol Branch, NCI, Bethesda, MD USA
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
REOPERATION; CLASSIFICATION; RADIOTHERAPY; GLIOMAS;
D O I
10.1200/JCO.2010.30.0582
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Despite initial treatment with surgical resection, radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) virtually always recurs. Surgery is sometimes recommended to treat recurrence. In this study, we sought to devise a preoperative scale that predicts survival after surgery for recurrent glioblastoma multiforme. Patients and Methods The preoperative clinical and radiographic data of 34 patients who underwent re-operation of recurrent GBM tumors were analyzed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. The factors associated with decreased postoperative survival (P =.05) were used to devise a prognostic scale which was validated with a separate cohort of 109 patients. Results The factors associated with poor postoperative survival were: tumor involvement of prespecified eloquent/ critical brain regions (P =021), Karnofsky performance status (KPS)= 80 (P =030), and tumor volume 50 cm3 (P =048). An additive scale (range, 0 to 3 points) comprised of these three variables distinguishes patients with good (0 points), intermediate (1 to 2 points), and poor (3 points) postoperative survival (median survival, 10.8, 4.5, and 1.0 months, respectively; P=.001). The scale identified three statistically distinct groups within the validation cohort as well (median survival, 9.2, 6.3, and 1.9 months, respectively; P = 001). Conclusion We devised and validated a preoperative scale that identifies patients likely to have poor, intermediate, and good relative outcomes after surgical resection of a recurrent GBM tumor. Application of this simple scale may be useful in counseling patients regarding their treatment options and in designing clinical trials.
引用
收藏
页码:3838 / 3843
页数:6
相关论文
共 15 条
[1]   REOPERATION IN THE TREATMENT OF RECURRENT INTRACRANIAL MALIGNANT GLIOMAS [J].
AMMIRATI, M ;
GALICICH, JH ;
ARBIT, E ;
LIAO, Y .
NEUROSURGERY, 1987, 21 (05) :607-614
[2]   Experimental approaches for the treatment of malignant gliomas [J].
Arko, Leopold ;
Katsyv, Igor ;
Park, Grace E. ;
Luan, William Patrick ;
Park, John K. .
PHARMACOLOGY & THERAPEUTICS, 2010, 128 (01) :1-36
[3]   Survival and functional status after resection of recurrent glioblastoma multiforme [J].
Barker, FG ;
Chang, SM ;
Gutin, PH ;
Malec, MK ;
McDermott, MW ;
Prados, MD ;
Wilson, CB .
NEUROSURGERY, 1998, 42 (04) :709-720
[4]  
Carson KA, 2007, J CLIN ONCOL, V25, P2601, DOI 10.1200/JCO.2006.08.1661
[5]  
*CENTR BRAIN TUM R, 2010, CENTR BRAIN TUM REG
[6]   Preoperative prognostic classification system for hemispheric low-grade gliomas in adults [J].
Chang, Edward F. ;
Smith, Justin S. ;
Chang, Susan M. ;
Lamborn, Kathleen R. ;
Prados, Michael D. ;
Butowski, Nicholas ;
Barbaro, Nicholas M. ;
Parsa, Andrew T. ;
Berger, Mitchel S. ;
McDermott, Michael M. .
JOURNAL OF NEUROSURGERY, 2008, 109 (05) :817-824
[7]  
DIRKS P, 1993, CAN J SURG, V36, P271
[8]   Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].
Friedman, Henry S. ;
Prados, Michael D. ;
Wen, Patrick Y. ;
Mikkelsen, Tom ;
Schiff, David ;
Abrey, Lauren E. ;
Yung, W. K. Alfred ;
Paleologos, Nina ;
Nicholas, Martin K. ;
Jensen, Randy ;
Vredenburgh, James ;
Huang, Jane ;
Zheng, Maoxia ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740
[9]   REOPERATION FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC ASTROCYTOMA [J].
HARSH, GR ;
LEVIN, VA ;
GUTIN, PH ;
SEAGER, M ;
SILVER, P ;
WILSON, CB .
NEUROSURGERY, 1987, 21 (05) :615-621
[10]   Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma [J].
Kreisl, Teri N. ;
Kim, Lyndon ;
Moore, Kraig ;
Duic, Paul ;
Royce, Cheryl ;
Stroud, Irene ;
Garren, Nancy ;
Mackey, Megan ;
Butman, John A. ;
Camphausen, Kevin ;
Park, John ;
Albert, Paul S. ;
Fine, Howard A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :740-745